Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis GS-US-384-1943
Description This study will evaluate the effects of the drug selonsertib on NASH (non-alcoholis steatohepatitis) and liver fibrosis.

The study visits will be in downtown Buffalo

If you are interested in this study, please contact the study coordinator below.
Objective The purpose of this study is to see if selonsertib is safe, well tolerated, and whether can reduce fibrosis and associated complications in subjects with cirrhosis fibrosis due to NASH.

Keywords: NASH, Non-alcoholic Steatohepatitis, liver, fibrosis, cirrhosis
Principal Investigator TALAL, ANDREW
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT03053050/
Status Open
Key Eligibility Nonalcoholic Steatohepatitis (NASH) Bridging (F3) Liver Fibrosis
Disease Group Digestive System; Liver Diseases
Treatment selonsertib (SEL; GS-4997)
Contact RICHARD REJMAN
716-878-3320
rmrejman@buffalo.edu